Lumacaftor Plus Ivacaftor Combination

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

Drug Information

Target Indication

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

Clinical Trial

Last updated: 12/3/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

VRTX

Vertex Pharmaceuticals Incorporated

Related Pipeline

Cystic Fibrosis

Cystic Fibrosis

Cystic Fibrosis

Cystic Fibrosis

Cystic Fibrosis

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts